Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller / Chief Accounting OfficerGlobeNewsWire • 09/03/21
Thursday Afternoon Analyst Upgrades and Downgrades: Apple, AutoDesk and More24/7 Wall Street • 08/19/21
Is the Options Market Predicting a Spike in Apellis (APLS) Stock?Zacks Investment Research • 08/11/21
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common StockGlobeNewsWire • 07/26/21
Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common StockGlobeNewsWire • 07/08/21
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement DisordersBenzinga • 07/01/21
Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven DiseasesGlobeNewsWire • 06/30/21
Apellis-Sobi Partnered Pegcetacoplan Shows Clinically Meaningful Improvements in Rare Blood Disorder StudyBenzinga • 05/25/21
Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNHPRNewsWire • 05/25/21
Apellis Stock Is Trading Higher On FDA Approval For Empaveli In Rare Blood DisorderBenzinga • 05/17/21
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)GlobeNewsWire • 05/14/21